JP4031478B2 - インフルエンザ血球凝集素多価ワクチンの製造方法 - Google Patents
インフルエンザ血球凝集素多価ワクチンの製造方法 Download PDFInfo
- Publication number
- JP4031478B2 JP4031478B2 JP2004360081A JP2004360081A JP4031478B2 JP 4031478 B2 JP4031478 B2 JP 4031478B2 JP 2004360081 A JP2004360081 A JP 2004360081A JP 2004360081 A JP2004360081 A JP 2004360081A JP 4031478 B2 JP4031478 B2 JP 4031478B2
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- vaccine
- seq
- amino acid
- hemagglutinin protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 101710154606 Hemagglutinin Proteins 0.000 title claims description 18
- 101710093908 Outer capsid protein VP4 Proteins 0.000 title claims description 18
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 title claims description 18
- 101710176177 Protein A56 Proteins 0.000 title claims description 18
- 206010022000 influenza Diseases 0.000 title claims description 15
- 239000000185 hemagglutinin Substances 0.000 title description 12
- 238000004519 manufacturing process Methods 0.000 title description 5
- 229940031348 multivalent vaccine Drugs 0.000 title 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 241000701447 unidentified baculovirus Species 0.000 claims description 13
- 229960005486 vaccine Drugs 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 208000037797 influenza A Diseases 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 241000238631 Hexapoda Species 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000002255 vaccination Methods 0.000 claims description 4
- 208000037798 influenza B Diseases 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 229960003971 influenza vaccine Drugs 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical group 0.000 description 8
- 101150039660 HA gene Proteins 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 241000845082 Panama Species 0.000 description 3
- 229940031567 attenuated vaccine Drugs 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 229940031418 trivalent vaccine Drugs 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229940124894 Fluzone Drugs 0.000 description 2
- 229940124873 Influenza virus vaccine Drugs 0.000 description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004360081A JP4031478B2 (ja) | 2004-12-13 | 2004-12-13 | インフルエンザ血球凝集素多価ワクチンの製造方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004360081A JP4031478B2 (ja) | 2004-12-13 | 2004-12-13 | インフルエンザ血球凝集素多価ワクチンの製造方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53561796A Division JP3757318B2 (ja) | 1993-09-13 | 1995-05-26 | インフルエンザ血球凝集素多価ワクチンの製造方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007136405A Division JP2007314538A (ja) | 2007-05-23 | 2007-05-23 | インフルエンザ血球凝集素多価ワクチンの製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005170945A JP2005170945A (ja) | 2005-06-30 |
| JP2005170945A5 JP2005170945A5 (enExample) | 2005-11-04 |
| JP4031478B2 true JP4031478B2 (ja) | 2008-01-09 |
Family
ID=34737425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004360081A Expired - Lifetime JP4031478B2 (ja) | 2004-12-13 | 2004-12-13 | インフルエンザ血球凝集素多価ワクチンの製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4031478B2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012502931A (ja) * | 2008-09-17 | 2012-02-02 | 上海天偉生物制薬有限公司 | サブユニットを殆ど含まない糖タンパク質組成物及びその製造方法 |
| US9085121B2 (en) | 1999-05-13 | 2015-07-21 | 3M Innovative Properties Company | Adhesive-backed articles |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ567817A (en) | 2005-11-01 | 2012-01-12 | Novartis Vaccines & Diagnostic | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
| JP6149213B2 (ja) | 2007-12-06 | 2017-06-21 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | インフルエンザウイルスに対する抗体およびその使用方法 |
-
2004
- 2004-12-13 JP JP2004360081A patent/JP4031478B2/ja not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9085121B2 (en) | 1999-05-13 | 2015-07-21 | 3M Innovative Properties Company | Adhesive-backed articles |
| JP2012502931A (ja) * | 2008-09-17 | 2012-02-02 | 上海天偉生物制薬有限公司 | サブユニットを殆ど含まない糖タンパク質組成物及びその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005170945A (ja) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3757318B2 (ja) | インフルエンザ血球凝集素多価ワクチンの製造方法 | |
| JP7250878B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| Paillot et al. | Vaccination against equine influenza: quid novi? | |
| US20120207785A1 (en) | Process for preparing an influenza seed virus for vaccine manufacture | |
| JP2014505681A (ja) | 改変インフルエンザヘマグルチニンタンパク質およびその使用 | |
| CN101636177A (zh) | 用于禽流感的基于重组改良型痘苗病毒安卡拉(mva)的疫苗 | |
| AU2009333208A1 (en) | Production of influenza vaccines | |
| JP2008522621A (ja) | 世界的に流行するトリインフルエンザに対して迅速に応答するためのワクチン | |
| US20200237898A1 (en) | Vaccines intelligently produced by epitope recombination (viper) for influenza | |
| Sączyńska et al. | A novel hemagglutinin protein produced in bacteria protects chickens against H5N1 highly pathogenic avian influenza viruses by inducing H5 subtype-specific neutralizing antibodies | |
| JP4031478B2 (ja) | インフルエンザ血球凝集素多価ワクチンの製造方法 | |
| KR20120131725A (ko) | 고병원성 조류인플루엔자 ａ ｈ５ｎ１ 바이러스 유사입자 및 이를 이용한 가금용 백신 | |
| US12102674B2 (en) | Universal influenza vaccine | |
| KR102529010B1 (ko) | 조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형 | |
| JP3918949B2 (ja) | インフルエンザ血球凝集素多価ワクチンの製造方法 | |
| CN113646047A (zh) | 减毒活流感疫苗组合物和用于制备其的方法 | |
| JP2007314538A (ja) | インフルエンザ血球凝集素多価ワクチンの製造方法 | |
| JP2009102416A (ja) | インフルエンザ血球凝集素多価ワクチンの製造方法 | |
| RU2315101C2 (ru) | Вакцинный штамм вируса гриппа а/17/калифорния/ 04/6 (н3n2) и донор аттенуации а/ленинград/134/17/к7/57 (н2n2) для его получения | |
| JP2014111650A (ja) | インフルエンザ血球凝集素多価ワクチンの製造方法 | |
| JP2013040205A (ja) | インフルエンザ血球凝集素多価ワクチンの製造方法 | |
| US20230321215A1 (en) | Avian influenza vaccines and methods of making same | |
| KR101302245B1 (ko) | 넓은 범위의 교차 방어능력을 갖는 신규한 보강 인플루엔자 백신 | |
| RU2159810C1 (ru) | Штамм вируса гриппа а/47/пекин/95/35(h1n1) для производства живой гриппозной интраназальной вакцины для детей | |
| RU2159811C1 (ru) | Штамм вируса гриппа а/17/пекин/95/25(h1n1) для производства живой гриппозной интраназальной вакцины для взрослых |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060215 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060301 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060512 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060606 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060512 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060906 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060914 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061206 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20061207 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070123 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070523 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070606 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070731 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070813 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071002 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071018 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101026 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111026 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121026 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121026 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131026 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| EXPY | Cancellation because of completion of term |